This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Reprints and Permissions Copyright Information Books from ASM Press MicrobeWorld Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Barchiesi, F Articles by Rinaldi, M G Search for Related Content PubMed PubMed Citation Articles by Barchiesi, F Articles by Rinaldi, M G

 Previous Article  |  Next Article 

Antimicrob Agents Chemother. 1994 July; 38(7): 1530-1533

In vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from oral cavities of patients infected with human immunodeficiency virus.

F Barchiesi, A L Colombo, D A McGough, A W Fothergill and M G Rinaldi

Fungus Testing Laboratory Department of Pathology, University of Texas Health Science Center, San Antonio 78284-7750.

ABSTRACT

A broth macrodilution technique, which was performed by following the recommendations provided by the National Committee for Clinical Laboratory Standards (document M27-P), was applied to study the in vitro activity of itraconazole against fluconazole-susceptible and -resistant Candida albicans isolates from the oral cavities of 100 patients infected with human immunodeficiency virus. The in vitro data demonstrated that itraconazole had good activity against the tested isolates; for 90% of all strains of C. albicans, MICs were 1 microgram/ml, and only one isolate was highly resistant to this triazole (MIC, > 16 micrograms/ml). However, the itraconazole MICs for the fluconazole-susceptible isolates were significantly lower than those for the fluconazole-resistant isolates; the MICs for 50 and 90% of the isolates tested were < or = 0.03 and 0.25 microgram/ml, respectively, for the fluconazole-susceptible isolates and 0.5 and 1 microgram/ml, respectively, for the fluconazole-resistant isolates (P = 0.00001). Our findings could be of clinical relevance because human immunodeficiency virus-infected patients who fail fluconazole therapy for oral and/or esophageal candidiasis may require itraconazole at doses higher than those used in standard therapy.

---

Antimicrob Agents Chemother. 1994 July; 38(7): 1530-1533

This article has been cited by other articles:

• Pfaller, M. A., Boyken, L., Hollis, R. J., Messer, S. A., Tendolkar, S., Diekema, D. J. (2005). In Vitro Susceptibilities of Clinical Isolates of Candida Species, Cryptococcus neoformans, and Aspergillus Species to Itraconazole: Global Survey of 9,359 Isolates Tested by Clinical and Laboratory Standards Institute Broth Microdilution Methods. J. Clin. Microbiol. 43: 3807-3810 [Abstract] [Full Text]  
• Arathoon, E. G., Gotuzzo, E., Noriega, L. M., Berman, R. S., DiNubile, M. J., Sable, C. A. (2002). Randomized, Double-Blind, Multicenter Study of Caspofungin versus Amphotericin B for Treatment of Oropharyngeal and Esophageal Candidiases. Antimicrob. Agents Chemother. 46: 451-457 [Abstract] [Full Text]  
• Boogaerts, M., Winston, D. J., Bow, E. J., Garber, G., Reboli, A. C., Schwarer, A. P., Novitzky, N., Boehme, A., Chwetzoff, E., De Beule, K., the Itraconazole Neutropenia Study Group*, (2001). Intravenous and Oral Itraconazole versus Intravenous Amphotericin B Deoxycholate as Empirical Antifungal Therapy for Persistent Fever in Neutropenic Patients with Cancer Who Are Receiving Broad-Spectrum Antibacterial Therapy: A Randomized, Controlled Trial. ANN INTERN MED 135: 412-422 [Abstract] [Full Text]  
• Muller, F.-M. C., Weig, M., Peter, J., Walsh, T. J. (2000). Azole cross-resistance to ketoconazole, fluconazole, itraconazole and voriconazole in clinical Candida albicans isolates from HIV-infected children with oropharyngeal candidosis. J Antimicrob Chemother 46: 338-341 [Full Text]  
• Barchiesi, F., Calabrese, D., Sanglard, D., Falconi Di Francesco, L., Caselli, F., Giannini, D., Giacometti, A., Gavaudan, S., Scalise, G. (2000). Experimental Induction of Fluconazole Resistance in Candida tropicalis ATCC 750. Antimicrob. Agents Chemother. 44: 1578-1584 [Abstract] [Full Text]  
• Walsh, T. J., Gonzalez, C. E., Piscitelli, S., Bacher, J. D., Peter, J., Torres, R., Shetti, D., Katsov, V., Kligys, K., Lyman, C. A. (2000). Correlation between In Vitro and In Vivo Antifungal Activities in Experimental Fluconazole-Resistant Oropharyngeal and Esophageal Candidiasis. J. Clin. Microbiol. 38: 2369-2373 [Abstract] [Full Text]  
• Ellepola, A.N.B., Samaranayake, L.P. (2000). Oral Candidal Infections and Antimycotics. CROBM 11: 172-198 [Abstract] [Full Text]  
• Henry, K. W., Cruz, M. C., Katiyar, S. K., Edlind, T. D. (1999). Antagonism of Azole Activity against Candida albicans following Induction of Multidrug Resistance Genes by Selected Antimicrobial Agents. Antimicrob. Agents Chemother. 43: 1968-1974 [Abstract] [Full Text]  
• de Bernardis, F., Mondello, F., Scaravelli, G., Pachì, A., Girolamo, A., Agatensi, L., Cassone, A. (1999). High Aspartyl Proteinase Production and Vaginitis in Human Immunodeficiency Virus-Infected Women. J. Clin. Microbiol. 37: 1376-1380 [Abstract] [Full Text]  
• Barone, J. A., Moskovitz, B. L., Guarnieri, J., Hassell, A. E., Colaizzi, J. L., Bierman, R. H., Jessen, L. (1998). Enhanced Bioavailability of Itraconazole in Hydroxypropylbeta -Cyclodextrin Solution versus Capsules in Healthy Volunteers. Antimicrob. Agents Chemother. 42: 1862-1865 [Abstract] [Full Text]  
• Tortorano, A. M., Viviani, M. A., Barchiesi, F., Arzeni, D., Rigoni, A. L., Cogliati, M., Compagnucci, P., Scalise, G. (1998). Comparison of Three Methods for Testing Azole Susceptibilities of Candida albicans Strains Isolated Sequentially from Oral Cavities of AIDS Patients. J. Clin. Microbiol. 36: 1578-1583 [Abstract] [Full Text]